Covington & Burling LLP operates as a limited liability partnership worldwide, with the practice in England and Wales conducted by an affiliated limited liability multinational partnership, Covington & Burling LLP, which is formed under the laws of the State of Delaware in the United States and authorized and regulated by the Solicitors Regulation Authority with registration number 77071..
On Wednesday, June 28, Miriam Guggenheim, partner and co-chair of the firm's Food, Drug and Device practice, will be speaking at the 11th Legal, Regulatory & Compliance Forum on Dietary Supplements held by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN). During the panel, "Understanding FDA’s Interpretation of the Drug Preclusion Clause: Tips for Fostering Innovation, Winning the "Race to Market" and Protecting Your Winning Investment in the Current Compliance Landscape," Miriam will share her insights on best practices and strategy development, as well as a look at the bigger picture, in regards to the FDA's approach to the drug preclusion clause.
For more information, and to register, visit the ACI's site.